The c-MET exon 14 skipping mutation exists in a variety of solid tumors, mainly in non-small cell lung cancer (NSCLC). The mutation rate in lung adenocarcinoma is about 3%, and the mutation rate in lung squamous cell carcinoma is about 2%, especially i, the mutation rate is as high as 22% in lung sarcomatoid carcinoma (PSC). Clinical studies have shown that c-MET inhibitors have a significant effect on patients with c-MET exon 14 skipping mutations, but have little effect on wild-type patients. Therefore, the detection of c-MET exon 14 skipping mutation is the premise and basis for guiding the use of c-MET inhibitors. Detection of c-MET exon 14 skipping mutation by a highly sensitive detection method is of great significance for improving lung cancer patients. It is of great significance to improve the survival rate, to prolong the survival period, to avoid excessive chemotherapy, and to improve the quality of life.

The human c-MET exon 14 skipping mutation detection kit developed by MEDx Translational Medicine is used to qualitatively detect c-MET exon 14 skipping mutations in vitro on RNA extracted from human tissue samples.